Pulmonary Hypertension in HFpEF and HFrEF
Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Guazzi, Marco [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Bimetallic diffusion modeling and temperature regulation during ball milling - Aureli, Matteo ELSEVIER, 2018, JACC, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:76 ; year:2020 ; number:9 ; day:1 ; month:09 ; pages:1102-1111 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jacc.2020.06.069 |
|---|
| Katalog-ID: |
ELV051192993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV051192993 | ||
| 003 | DE-627 | ||
| 005 | 20230626031659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2020.06.069 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica |
| 035 | |a (DE-627)ELV051192993 | ||
| 035 | |a (ELSEVIER)S0735-1097(20)35936-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Guazzi, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary Hypertension in HFpEF and HFrEF |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. | ||
| 520 | |a Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. | ||
| 650 | 7 | |a pulmonary hypertension |2 Elsevier | |
| 650 | 7 | |a HFpEF |2 Elsevier | |
| 650 | 7 | |a HFrEF |2 Elsevier | |
| 700 | 1 | |a Ghio, Stefano |4 oth | |
| 700 | 1 | |a Adir, Yochai |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Aureli, Matteo ELSEVIER |t Bimetallic diffusion modeling and temperature regulation during ball milling |d 2018 |d JACC |g New York, NY |w (DE-627)ELV000161896 |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:9 |g day:1 |g month:09 |g pages:1102-1111 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jacc.2020.06.069 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 9 |b 1 |c 0901 |h 1102-1111 |g 10 | ||
| author_variant |
m g mg |
|---|---|
| matchkey_str |
guazzimarcoghiostefanoadiryochai:2020----:umnrhpresoihp |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2020 |
| allfields |
10.1016/j.jacc.2020.06.069 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica (DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Guazzi, Marco verfasserin aut Pulmonary Hypertension in HFpEF and HFrEF 2020transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier Ghio, Stefano oth Adir, Yochai oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 https://doi.org/10.1016/j.jacc.2020.06.069 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 76 2020 9 1 0901 1102-1111 10 |
| spelling |
10.1016/j.jacc.2020.06.069 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica (DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Guazzi, Marco verfasserin aut Pulmonary Hypertension in HFpEF and HFrEF 2020transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier Ghio, Stefano oth Adir, Yochai oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 https://doi.org/10.1016/j.jacc.2020.06.069 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 76 2020 9 1 0901 1102-1111 10 |
| allfields_unstemmed |
10.1016/j.jacc.2020.06.069 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica (DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Guazzi, Marco verfasserin aut Pulmonary Hypertension in HFpEF and HFrEF 2020transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier Ghio, Stefano oth Adir, Yochai oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 https://doi.org/10.1016/j.jacc.2020.06.069 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 76 2020 9 1 0901 1102-1111 10 |
| allfieldsGer |
10.1016/j.jacc.2020.06.069 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica (DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Guazzi, Marco verfasserin aut Pulmonary Hypertension in HFpEF and HFrEF 2020transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier Ghio, Stefano oth Adir, Yochai oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 https://doi.org/10.1016/j.jacc.2020.06.069 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 76 2020 9 1 0901 1102-1111 10 |
| allfieldsSound |
10.1016/j.jacc.2020.06.069 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica (DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Guazzi, Marco verfasserin aut Pulmonary Hypertension in HFpEF and HFrEF 2020transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier Ghio, Stefano oth Adir, Yochai oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 https://doi.org/10.1016/j.jacc.2020.06.069 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 76 2020 9 1 0901 1102-1111 10 |
| language |
English |
| source |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 |
| sourceStr |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:76 year:2020 number:9 day:1 month:09 pages:1102-1111 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
pulmonary hypertension HFpEF HFrEF |
| dewey-raw |
600 |
| isfreeaccess_bool |
false |
| container_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| authorswithroles_txt_mv |
Guazzi, Marco @@aut@@ Ghio, Stefano @@oth@@ Adir, Yochai @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000161896 |
| dewey-sort |
3600 |
| id |
ELV051192993 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051192993</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626031659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2020.06.069</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051192993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(20)35936-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guazzi, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pulmonary Hypertension in HFpEF and HFrEF</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pulmonary hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HFpEF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HFrEF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghio, Stefano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adir, Yochai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:76</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:9</subfield><subfield code="g">day:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:1102-1111</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2020.06.069</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">76</subfield><subfield code="j">2020</subfield><subfield code="e">9</subfield><subfield code="b">1</subfield><subfield code="c">0901</subfield><subfield code="h">1102-1111</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Guazzi, Marco |
| spellingShingle |
Guazzi, Marco ddc 600 bkl 51.00 bkl 51.32 Elsevier pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Pulmonary Hypertension in HFpEF and HFrEF |
| authorStr |
Guazzi, Marco |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000161896 |
| format |
electronic Article |
| dewey-ones |
600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
600 690 VZ 51.00 bkl 51.32 bkl Pulmonary Hypertension in HFpEF and HFrEF pulmonary hypertension Elsevier HFpEF Elsevier HFrEF Elsevier |
| topic |
ddc 600 bkl 51.00 bkl 51.32 Elsevier pulmonary hypertension Elsevier HFpEF Elsevier HFrEF |
| topic_unstemmed |
ddc 600 bkl 51.00 bkl 51.32 Elsevier pulmonary hypertension Elsevier HFpEF Elsevier HFrEF |
| topic_browse |
ddc 600 bkl 51.00 bkl 51.32 Elsevier pulmonary hypertension Elsevier HFpEF Elsevier HFrEF |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s g sg y a ya |
| hierarchy_parent_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| hierarchy_parent_id |
ELV000161896 |
| dewey-tens |
600 - Technology 690 - Building & construction |
| hierarchy_top_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000161896 |
| title |
Pulmonary Hypertension in HFpEF and HFrEF |
| ctrlnum |
(DE-627)ELV051192993 (ELSEVIER)S0735-1097(20)35936-2 |
| title_full |
Pulmonary Hypertension in HFpEF and HFrEF |
| author_sort |
Guazzi, Marco |
| journal |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| journalStr |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
1102 |
| author_browse |
Guazzi, Marco |
| container_volume |
76 |
| physical |
10 |
| class |
600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Guazzi, Marco |
| doi_str_mv |
10.1016/j.jacc.2020.06.069 |
| dewey-full |
600 690 |
| title_sort |
pulmonary hypertension in hfpef and hfref |
| title_auth |
Pulmonary Hypertension in HFpEF and HFrEF |
| abstract |
Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. |
| abstractGer |
Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. |
| abstract_unstemmed |
Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
9 |
| title_short |
Pulmonary Hypertension in HFpEF and HFrEF |
| url |
https://doi.org/10.1016/j.jacc.2020.06.069 |
| remote_bool |
true |
| author2 |
Ghio, Stefano Adir, Yochai |
| author2Str |
Ghio, Stefano Adir, Yochai |
| ppnlink |
ELV000161896 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.jacc.2020.06.069 |
| up_date |
2024-07-06T19:35:03.069Z |
| _version_ |
1803859528850079744 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051192993</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626031659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2020.06.069</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001220.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051192993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(20)35936-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guazzi, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pulmonary Hypertension in HFpEF and HFrEF</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pulmonary hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HFpEF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HFrEF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghio, Stefano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adir, Yochai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:76</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:9</subfield><subfield code="g">day:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:1102-1111</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2020.06.069</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">76</subfield><subfield code="j">2020</subfield><subfield code="e">9</subfield><subfield code="b">1</subfield><subfield code="c">0901</subfield><subfield code="h">1102-1111</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.399275 |